Leuprolide
Brand Names: Camcevi, Lupron
Methodology & AI Transparency ⓘ
Leuprolide Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Listed in the U.S.
- 2 Real-world patient consensus: Real-world cohort score of 75% across 5 de-identified Leuprolide entries.
- 3 Typical cash cost range: Dispensing cost comparison spans $64.02 mail/discount cash up to $156.85 uninsured retail (federal NADAC $258.8691).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Leuprolide): nausea (7.6%), headache (7.7%), dizziness (5.4%).
Ask our AI Specialists anything about Leuprolide
Leuprolide Mechanism, CYP450 Pathways & DailyMed Monograph
Listed in the U.S. FDA National Drug Code Registry (69448-014, 69448-023), Leuprolide serves as a subcutaneous-route prescription gonadotropin releasing hormone receptor agonist (42 mg/.37g Injection, Emulsion, manufactured/labeled by Accord BioPharma, Inc.) utilized in evidence-based specialty and primary care protocols.
Upon subcutaneous-route administration of 42 mg/.37g Injection, Emulsion, Leuprolide (manufactured/labeled by Accord BioPharma, Inc.; NDC 69448-014, 69448-023) engages gonadotropin releasing hormone receptor agonist biochemical pathways to achieve steady-state therapeutic response balanced against organ-specific metabolic elimination.
Systemic exposure to Leuprolide reflects Complete (~100%) parenteral systemic delivery for Leuprolide (42 mg/.37g Injection, Emulsion) absorption kinetics and dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of leuprolide, sustaining receptor engagement across a Mean elimination half-life of 7 to 20 hours across adult Leuprolide dosing half-life window (rapid intravascular/parenteral onset within 15–45 minutes after leuprolide administration response profile).
Dosing protocols (42 mg/.37g Injection, Emulsion or 1mg/0.2ml Kit) balance efficacy (75.00% patient satisfaction across 5 logs) against headache (7.7% of reports), nausea (7.6% of reports), dizziness (5.4% of reports), with strict avoidance in history of severe allergic sensitivity to leuprolide active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2026-07-01 leuprolide labeling.
Verify medication reconciliation lists so Leuprolide is not inadvertently duplicated with another gonadotropin releasing hormone receptor agonist.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Leuprolide dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of severe allergic sensitivity to Leuprolide active moiety or formulation vehicle
- Acute clinical instability or interacting polypharmacy excluded under 2026-07-01 Leuprolide labeling
Logged Side-Effect Incidence (5 Reports)
Leuprolide Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Leuprolide)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Ulipristal acetate compared with leuprorelin acetate for Japanese women with No notable AEs occurred because of the UPA treatment, and the incidence of AEs in the UPA group was comparable with that of AEs in the LEU group. Fertility and sterility • 2021-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33715871 ↗ |
| Can This Approach Help? Inside the Latest Research on Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces Safety profiles of both medications were comparable, although menses returned earlier in patients taking REL, a huge benefit for women who plan to conceive after treatment. Fertility and sterility • 2022-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34895700 ↗ |
| New Insights on Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate: What a 934-Participant Study Found Oral relugolix is a therapeutic option with similar patient-reported HRQOL to leuprolide, providing an oral option for androgen deprivation therapy associated with a more rapid testosterone reduction. European urology • 2023-12-15 • Phase III Randomized Trial | N = 934 | 87/100 | PMID 37833178 ↗ |
| New Insights on Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced: What a 934-Participant Study Found Oral relugolix had faster and more complete recovery of testosterone to normal levels after treatment discontinuation than leuprolide acetate in a subset of men from the HERO study. European urology oncology • 2024-08-15 • Phase III Randomized Trial | N = 934 | 87/100 | PMID 38143206 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinical characteristics of ovulation induction with human menopausal Cycle fecundity was 0.16 for hMG alone cycles, and 0.27 for leuprolide with hMG cycles, which were not statistically different. Fertility and sterility • 1989-12-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 2512181 ↗ |
Leuprolide Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $258.8691/unit (~$7766.07/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $64.02 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $156.85 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 5 Anonymous DotMD Community Micro-Logs | $73.62 / mo | View logs ↓ |
| Hone Health Hormone & At-Home Biomarker Lab (Licensed Telehealth Cash Program) | State-licensed clinician review • ~3d mail fulfillment | $65.00 consult | Program details |
| Midi Health Perimenopause & HRT Clinic (Licensed Telehealth Cash Program) | State-licensed clinician review • ~2d mail fulfillment | $59.00 consult | Program details |
Leuprolide Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Leuprolide RxNorm Concept ID | RXN-69448014-1923 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $258.8691 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $156.85 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $64.02 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 75.00% Worth It (5 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Leuprolide Patient Community, Cohort Filters & Dosage Logs
Deterministic Leuprolide reference combining NIH RxNorm (RXN-69448014-1923), Medicaid NADAC ($258.8691/unit), and anonymous cohort outcomes (75% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Leuprolide community threads and patient logs by age, biological sex, dosage, and treatment duration.